Companies
Comprehensive database of innovative Biophama companies in Korea
BQURA Company Database
Find out most innovative Korean Biopharma companies
Onconic Therapeutics
Biotech, PharmaOnconic Therapeutics, established in 2020 and based in Seoul, South Korea, is an innovative biopharmaceutical company focused on developing advanced cancer treatments and gastrointestinal therapies. As a subsidiary of Jeil Pharma Holdings, Onconic has made notable progress with its flagship product, Jaqbo (Zastaprazan), which is designed to treat gastroesophageal reflux disease (GERD) and represents Korea's 37th domestically developed new drug.
Mustbio
BiotechMustbio leverage our innovative platforms, BICSTA™ and STARKINE™, to develop tumor-directed multi-specific antibodies with broader therapeutic potential. Mustbio is committed to creating next-generation immuno-oncology therapies, ensuring that patients receive safer and more effective treatment options. Through continuous research and development, and active collaboration with global partners, we aim to revolutionize cancer care and improve patient outcomes.
Neoimmunetech
BiotechFounded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. At NIT, we strive to expand the therapeutic horizon in Immuno-Oncology and Infectious Diseasesby greatly reducing the fatality and morbidity of life-threatening and debilitating diseases. Led by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science driven and patient focused. We believe that with NT-I7, the only clinical-stage long-acting human IL-7, we can enhance the body’s immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases. We have a profound belief, rooted in our science, that we have the power to transform patient care with unique assets like NT-I7, and are committed to the pursuit of discovering their full potential in treating various diseases.
Spark Biopharma
BiotechSPARK Biopharma, founded in 2016 in Seoul, South Korea, is a pioneering biotech company specializing in innovative drug discovery and development. At the core of their operations are proprietary platforms such as pDOS Library, Seoul-Fluor, and FITGE/TS-FITGE, which drive their research in immuno-oncology and other therapeutic areas. These technologies enable more efficient drug candidate identification and optimization. Despite its young age, SPARK Biopharma has secured significant funding, including a 25 billion won Series C investment in 2023, fueling its ambitious research projects. With a team of about 30 experts and plans for an IPO in 2024, SPARK Biopharma is positioned to make substantial contributions to biotechnology and drug development, particularly in the field of cancer immunotherapy.
AbTis
Biotech, R&D ServiceAbTis is a bio-technology company which is specialized in antibody-drug conjugates (ADC) linker platform with its own proprietary technology. We are developing the 3rd generation of ADCs to improve outcomes for cancer patients with pipelines designed to enhance the safety and efficacy of the current ADCs by applying AbTis’ linker platform, AbClick®. This technology is applicable to 'off-the-shelf' antibodies without any modification as well as it can be conjugated site-selectively to antibodies. AbTis aims to develop innovative pipelines to create positive economic impact and long-term value, improved quality of life for the patients worldwide.%201/original.png)
Xcell Therapeutics
BiotechXcell was established in September 2015 and is engaged in the research, development, and production of cell culture media suitable for advanced biopharmaceuticals (CGT). Based on ACF essential, it has built a cell-customized media development platform technology by incorporating significance scoring data for candidate ingredients specific to different cell types and the know-how gained from the media development process. The company's media development and manufacturing technology has been recognized as a core strategic technology in the "Key Cell and Material Manufacturing Technology for Advanced Biopharmaceutical Production" field by the Ministry of Trade, Industry, and Energy.
S.BIOMEDICS
BiotechS.BIOMEDICS develops therapies using a variety of cells, including somatic cells, immune cells, adult stem cells, and embryonic stem cells. It also manufactures and sells CFC-FECS-DF (a cosmetic ingredient). The company owns Esthefarm, a subsidiary that specializes in the manufacturing and sales of skincare products.
GENEONE Lifescience
BiotechA biopharmaceutical company dedicated to the research, development and contract manufacturing of nucleic acid-based biopharmaceuticals, including DNA and RNA vaccines, and to the development of novel small molecule therapeutics.%203/original.png)
Hanall Biopharma
Pharma, BioThe company produces and sells around 160 specialized and general medicines based on a diverse portfolio that includes the endocrine, circulatory, and urinary systems. Since 2004, it has built an R&D infrastructure by securing key research personnel and expanding research facilities through corporate innovation in global new drug R&D. It is currently researching Anti-TNF biopharmaceuticals and new target anticancer immunotherapeutic antibodies that strengthen the body's anticancer immune response to treat cancer.
Ensol Bioscience
BiotechAs a bio big data-based biopharmaceutical company that develops global innovative new drugs for diseases without therapeutic alternatives worldwide, such as degenerative disc, degenerative arthritis, TNBC, Alzheimer’s disease and type 1 diabetes, Ensol Biosciences applies bio big data-based BT/IT convergence technology from the aspects of drug efficacy, mechanism and toxicity, and side effects to develop outstanding drugs with high potential, and works on various discoveries and clinical trial phases systematically.
QURIENT
BiotechFounded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network. Qurient mainly engages in value creation between early discovery to clinical proof-of-concept. The particular concentration in the value chain creates more efficient organizational structure with clear focus on innovation. Qurient believes late stage development is better handled by fully integrated pharmaceutical/biotech industry with proper marketing function in the therapeutic area. Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders.
G2GBio
BiotechG2GBIO is addressing this challenge by advancing treatments for chronic diseases through our proprietary InnoLAMP (Innovative Long-Acting Microsphere Platform) technology. We are very proud that our unique approach ensures the production of high-quality, uniform microsphere injectables on a commercial scale. With InnoLAMP, G2GBIO is well-positioned to expand globally and continuously innovate, aiming to bring new, effective drugs to the market.